Recent News

• 09.16.2025 - Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
• 09.03.2025 - Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
• 08.20.2025 - Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
• 08.14.2025 - Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.14.2025 - Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.06.2025 - Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
• 07.16.2025 - Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
• 07.09.2025 - Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Recent Filings

• 09.09.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 09.03.2025 - 8-K Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.01.2025 - 8-K Current report
• 08.01.2025 - 8-K Current report
• 08.01.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.31.2025 - 424B5 Prospectus [Rule 424(b)(5)]